:
KRAS is the most common oncogene to be mutated in lung cancer, and therapeutics directly
targeting KRAS have proven to be challenging. The mutations of KRAS are associated with poor prognosis,
and resistance to both adjuvant therapy and targeted EGFR TKI. EGFR TKIs provide significant
clinical benefit for patients whose tumors bear EGFR mutations. However, tumors with KRAS mutations
rarely respond to the EGFR TKI therapy. Thus, combination therapy is essential for the treatment
of lung cancers with KRAS mutations. EGFR TKI combined with inhibitors of MAPKs, PI3K/mTOR,
HDAC, Wee1, PARP, CDK and Hsp90, even miRNAs and immunotherapy, were reviewed. Although
the effects of the combination vary, the combined therapeutics are one of the best options at present to
treat KRAS mutant lung cancer.
Synergistic combination therapy of lung cancer using lipid-layered cisplatin and oridonin co-encapsulated nanoparticles
